FAYETTEVILLE, Ark., Sept. 28, 2026 — HeartX, powered by HTA and MedAxiom — along with leading cardiovascular programs across the country — has selected five startup healthcare companies to participate in the 2026 accelerator program.

HeartX is a cardiovascular-focused healthcare accelerator that connects accomplished, early-stage companies with cardiovascular providers to facilitate pilot projects and clinical studies designed to validate innovative technologies in real-world care settings. Each company selected for the 2026 cohort will receive $150,000 in investment capital and is guaranteed at least one pilot project or clinical study with a participating cardiovascular program.

The five companies selected for the 2026 HeartX program are:

Flow Medical — Chicago, Illinois, USA
Flow Medical is developing technology to advance the treatment of pulmonary embolism through a personalized approach to catheter-directed thrombolysis. Its all-in-one angiography, infusion and monitoring catheter provides physicians with real-time feedback on clot resolution.

Mode Sensors — Trondheim, Norway
Mode Sensors develops wearable technology for continuous, non-invasive fluid monitoring. Its ReBalans® system uses advanced biosensors to provide real-time information about a patient’s fluid status.

Noah Labs — Berlin, Germany
Noah Labs develops AI-powered technology for remote monitoring and earlier detection of worsening heart failure. Its platform combines telemonitoring with Noah Labs Vox™, an AI-based voice analysis technology designed to detect signs of cardiac decompensation before hospitalization.

Galenband — Galway, Ireland
Galenband is developing a wearable cardiac telemetry system designed to continuously monitor cardiac function for up to 90 days. The system combines medical-grade sensors with automated data transmission and AI-supported analysis to help clinicians identify cardiac abnormalities while providing patients with a non-invasive alternative to implantable monitoring devices.

Omini — Suresnes, France
Omini is developing a point-of-care blood biomarker monitoring platform for patients with chronic diseases. Its portable system uses multiplex electrochemical biosensor technology to measure multiple blood biomarkers from a single capillary blood sample, providing clinicians with information that can support therapy adjustments and ongoing disease management.

“The companies selected for this year’s HeartX cohort are tackling some of the most persistent challenges in cardiovascular care — from identifying deterioration sooner to giving clinicians better information to personalize treatment,” said Jeff Stinson, director of HTA. “What makes HeartX unique is the opportunity to move those technologies into direct collaboration with our providers. We’re excited to see what these five companies can accomplish with access to HeartX clinicians, patients and real-world care settings.”

“Meaningful innovation happens when emerging technologies are developed alongside the clinicians and organizations that will ultimately use them,” said Joe Sasson, PhD, MedAxiom’s chief commercial officer and executive vice president of Ventures. “The 2026 HeartX cohort brings together solutions addressing a diverse range of cardiovascular challenges. We look forward to helping these companies gain the clinical insights, relationships and validation they need to advance their technologies and their impact on patient care.”

Representatives from participating cardiovascular programs across the country, HTA and MedAxiom, evaluated applicants and selected companies with technologies that have the potential to advance cardiovascular innovation and care.

The 2026 HeartX program will kick off at MedAxiom’s CV Transforum conference in Denver, Colorado, Oct. 22-24.

More information about HeartX can be found at HeartXAccelerator.com.

ABOUT HEALTHTECH ARKANSAS
HTA helps to drive innovation for healthcare provider organizations and clinical engagement for startup companies. Its flagship accelerator, HeartX, recruits worldwide for the most accomplished cardiovascular-focused startups in the areas of digital health, medical devices, and diagnostics. Those companies accepted into the program are guaranteed facilitated hospital pilot projects and clinical trials with leading cardiology practices around the country, along with financial investment, mentoring and exposure to the HeartX network. More information can be found at HealthTechArkansas.com.

ABOUT MEDAXIOM
MedAxiom, an American College of Cardiology Company, is the cardiovascular community’s premier source for organizational performance solutions. MedAxiom is transforming cardiovascular care by combining the knowledge and power of hundreds of cardiovascular organization members, thousands of administrators, clinicians and revenue cycle experts, and dozens of industry partners. Through the delivery of proprietary tools, smart data and proven strategies, MedAxiom helps cardiovascular organizations achieve the Quadruple Aim of better outcomes, lower costs, improved patient experience and improved clinician experience. Learn more at MedAxiom.com.

For more information, contact:
Jeff Stinson
501.766.0633
[email protected] 

SOURCE HTA

‘Protostar’ Power Node Prototype Ready to Launch at Vandenberg Space Force Base

JACKSONVILLE, Fla., Sept. 28, 2026 — Star Catcher Industries, Inc. (“Star Catcher”), the pioneering energy company building the first power grid in space, has its prototype power node, Protostar, prepared for launch at Vandenberg Space Force Base. Launching aboard SpaceX’s Transporter-18 mission scheduled for October 2026, the Protostar mission aims to conduct a landmark power beaming demonstration between two untethered spacecraft, a feat that has never been achieved. This mission is a key milestone in actualizing the orbital energy infrastructure that will power the next era of space operations and exploration.

Since the company’s founding in 2024, Star Catcher has successfully demonstrated its power beaming technology terrestrially, including setting a world record for optical power beaming at NASA’s Kennedy Space Center. In late 2025, the company also completed Sextant Alpha, an on-orbit demonstration mission of their proprietary spacecraft acquisition and tracking software. Star Catcher leveraged the data from these demonstrations to build and ship Protostar on an accelerated timeline.

“It takes an extraordinary engineering team to build, validate, and ship a space-qualified orbital power beaming spacecraft within two years of inception,” says Michael Snyder, co-founder and CTO of Star Catcher. “This mission will yield critical operational data in real-world orbital conditions that will directly support the build out of our commercial power grid in space.”

Protostar is the first end-to-end prototype of the company’s core technology stack on orbit: energy harvesting, satellite acquisition and tracking, and energy transmission. Following launch and commissioning, Protostar will deploy and track a CubeSat, to which it will beam measurable power to off-the-shelf solar panels, validating commercial power beaming operations.

Upon completion, this will be the world’s first optical power beamed between two free-flying spacecraft — a technological advancement that will enable on-demand wireless power transmission and act as the foundation of Star Catcher’s orbital power grid.

“Every major application driving the space economy — from real-time national security intelligence to AI-powered orbital computing and Earth observation — is limited by power,” said Andrew Rush, co-founder and CEO of Star Catcher. “We are closer to activating an orbital power grid than most can imagine; flying this prototype in only two years is meaningful evidence of the capability of our team and what’s to come.”

Star Catcher has publicly announced ten major commercial Power Purchase Agreements (PPAs) with leading space companies such as Starcloud, Loft Orbital, Astro Digital, and Aethero. These agreements, along with over 40 Letters of Intent (LOIs), a $60M Strategic Funding Increase (STRATFI) Award from the United States Space Force, and $88M in venture capital, have enabled Star Catcher’s rapid technology advancement. The company has already begun development on its follow-on satellite to beam operational levels of orbital power, is actively recruiting to more than double its team size, and is building out a new 100,000 square foot headquarters in Jacksonville, FL.

For more information, please visit www.star-catcher.com

For press inquiries, please contact Daniel Sherman at [email protected]

About Star Catcher

Star Catcher is an energy company building a power grid in space, providing the infrastructure to enable the next generation of spacecraft and advanced missions. Star Catcher removes power as a limiting factor for spacecraft, allowing continuous mission execution, increased operational endurance, and the ability to support higher power payloads without redesigning existing platforms. Founded in 2024 by Andrew Rush and Michael Snyder (Made In Space, Redwire), alongside Bryan Lyandvert (T-Bird Capital, Amazon), the company has raised $88M to date from B Capital, Shield Capital, Cerberus Ventures, Initialized Capital, among others. Based in Jacksonville, FL, the company currently holds the world record for optical power beaming.

SOURCE Star Catcher Industries, Inc.

NEW YORK, Sept. 28, 2026 — Independent Sponsors and emerging investment firms compete for the same deals as established private equity, without the in-house origination and value creation teams, or data infrastructure, those larger or more established investment firms run. XS Global (“XS”) launches today to close the capability gap between leaner investment firms and those with deep operational infrastructure, founded by technology veterans Nick Hunter and Akash Patel.

A 2026 study from the Institute for Private Capital and UNC Kenan-Flagler Business School¹ found average gross returns of 2.9x invested capital and a 29% IRR on exited Independent Sponsor-led deals of the deals in their study, ahead of comparable institutional buyouts, without a corresponding increase in loss frequency or severity. Citrin Cooperman’s 2026 Independent Sponsor Report² backs this up from the Sponsor side: among those who have had a liquidity event, 84% of the Sponsors in their study returned 3x or more to their respective investors this year, up from 57% in 2023.

XS was formed on the hypothesis that even without the value-creation resources larger firms have, Independent Sponsors and smaller firms have been able to deliver alpha, and that with these capabilities this part of the market would continue to evolve and consistently deliver strong performance. Therefore, XS has created the internal capacity required to compete on an institutional level, including origination from thesis-to-close to add-on activity, live data across every company owned, and deeper operating expertise.

The XS system is an integrated value creation platform that maps markets end-to-end and scores them against an investor’s deal prospects, EBITDA focus, investment thesis, and portfolio company M&A roadmap, at a scale otherwise reserved for large PE firms with large analyst headcounts.

Nick Hunter and Akash Patel co-founded XS after years of building enterprise technology together at pureIntegration. Hunter spent over 28 years working across media, adtech, and software engineering. A founding member of pureIntegration, he helped scale it to $20M in revenue and 150 professionals and led its pivot to a product model. Patel brings over two decades of enterprise systems integration and technology program leadership from Deloitte Consulting, AT&T, and Walgreens Boots Alliance, helping deliver $200M in new revenue through data modernization.

XS has launched with an existing solution suite that was originally ideated and incubated by a North American private equity firm, with early clients being onboarded onto the solutions today.

Speaking to their founding thesis, Nick Hunter, Co-founder of XS, said, “The largest funds don’t win on judgement alone; they win on the capability they build around it. XS gives that capability to the firms that could never afford to build it, allowing a lean investment firm to run its deals and companies the way an investment firm of two hundred does.”

Independent Sponsors, family offices, and boutique investment firms are some of the most active lower-middle market (“LMM”) agents, building essential services businesses into revenue-generating and acquisitive enterprises, and bringing those platforms to the institutional market. Capital is following them there: Citrin Cooperman’s 2026 Independent Sponsor Report² found that institutional LPs are increasingly treating Independent Sponsor-led deals as one of the few ways to access LMM returns at scale.

The same Citrin Cooperman report found that most Independent Sponsor firms run with two or three principals and minimal staff, limiting both the opportunities they can evaluate and the portfolio companies they can actively manage, even as larger PE firms push further into the lower-middle market for the same value creation potential. AI is already closing that gap: 79% of Independent Sponsors surveyed expect it to meaningfully reshape the model within three years, particularly in sourcing and diligence, the exact areas XS’s system is built around.

XS is live now, working with its first cohort of Independent Sponsors and investment firms ahead of a broader rollout in the coming months.

PRESS CONTACT 

Maeve Couch
[email protected] 
(347) 680-3601

About XS Global

XS gives Independent Sponsors and investment firms the value creation capability large funds build in-house: origination from thesis-to-close to add-on activity, live data across every company owned, and the operating professionals to move the numbers. One system, from the first deal through the hold to exit.

For more information, please visit https://xs.global/.

SOURCE XS Global

BOCA RATON, Fla. and NEW YORK, Sept. 28, 2026 — Fifth Ocean Capital, a private equity firm focused on partnering with founder-owned businesses, is pleased to announce a strategic investment in Complete Production Resources (CPR), in partnership with Tartan Investment Partners. CPR is a full-service live event production solution and equipment rental provider.

With headquarters in Orlando, Florida, CPR delivers turnkey audio, lighting, video, staging, and backline solutions to the production support market across the United States. Founded in 2010, CPR has earned its well-deserved reputation as one of the Southeast’s most trusted live event production solution providers through an unwavering commitment to expert craft and execution. The company delivers meticulously implemented 360° turnkey production services to a wide-ranging client base spanning corporate events, live entertainment, sporting events, cruise lines, universities, theme parks, venue support, and community organizations.

Fifth Ocean and Tartan are partnering with the CPR team to help accelerate the business’s next phase of growth, including investing in talent and technology, expanding its geographic presence, broadening its equipment inventory, and pursuing strategic add-on acquisitions that extend its services and client relationships.

Kelly Greene, CEO and co-founder, will remain a significant shareholder and continue to lead CPR. “We are thrilled to partner with Fifth Ocean and Tartan,” said Greene. “They have a long track record of supporting operators, scaling businesses, and funding growth initiatives. Our clients can count on the exact same team, values, and relentless commitment to execution they’ve trusted for years. This partnership gives us the resources to expand our inventory, enhance service capabilities, and support our clients on an even broader scale.”

Denis McEvoy, Managing Partner at Fifth Ocean, noted: “We look to partner with owners, like Kelly, who have built something special. The shift toward experiential events remains one of the most durable trends in consumer and corporate markets. CPR has the client relationships, equipment depth, and operational expertise to capitalize on that demand in a meaningful way. We look forward to backing Kelly and his team as they expand CPR’s geographic footprint and service capabilities.”

Peter Campbell, Managing Partner of Tartan Investment Partners, stated: “Our firm believes deeply in the staying power of live events, and we bring extensive investing and operating experience in the sector. What attracted us to CPR is Kelly — an owner who has spent decades building genuine trust across the industry, evidenced by the tenure and recurrence of client relationships. Live events are mission-critical, and CPR consistently delivers best-in-class execution across all aspects of the ecosystem. We’re proud to partner with CPR and look forward to helping scale this exceptional business.”

About Complete Production Resources

Complete Production Resources is a full-service live event production solutions and equipment rental provider, specializing in turnkey audio, lighting, video, staging, and backline solutions. Founded in 2010, the company partners with touring artists, corporations, universities, municipalities, sports and live event venue operators, theme parks and other event hosts looking for a one stop shop. For more information about CPR, visit www.completeproductionresources.com.

About Fifth Ocean

Fifth Ocean Capital Management is a Boca Raton, FL-based private equity firm focused on partnering with entrepreneurs, families, and ownership-minded management teams to invest in exceptional companies at growth inflection points. The firm leverages additional resources, expertise, and capital to drive both organic and inorganic growth, cultivating long term value for all stakeholders. Growth-oriented, Fifth Ocean seeks to generate superior outcomes through entrepreneurial business-building initiatives across business services, healthcare services, consumer and manufacturing sectors. For additional information, please visit www.fifthoceancapital.com.

About Tartan

Tartan Investment Partners is a New York, NY based independent sponsor investing in founder-led companies that provide critical technology and services across sports, entertainment, and consumer lifestyle sectors, with a focus on North America. The firm is built on combining investment discipline with experienced operators, providing sector-specific value creation and comprehensive operating insights to help founders scale their businesses. Learn more at www.tartaninvestmentpartners.com.

Contact Denis McEvoy at [email protected] and Michael Filler at [email protected] regarding new opportunities.

Media Contact:
Fifth Ocean
(561) 759-8399
[email protected] 

SOURCE Fifth Ocean

Strategic expansion strengthens Finalsite’s mission to help schools deliver meaningful, connected experiences for families across every interaction.

GLASTONBURY, Conn., Sept. 28, 2026 — Finalsite, a leading K–12 platform for school engagement, enrollment and communications, has expanded its payments capabilities through its recent acquisition of RevTrak, a leading digital payments provider serving more than 13,000 schools nationwide.

RevTrak builds on Finalsite’s existing tuition and billing solutions by extending its reach across everyday school payments—from meals and athletics to activities, events and fees. For more than 30 years, RevTrak has helped schools simplify how they collect, manage and track money, supporting the shift from cash, checks and manual processes to digital payments. Its technology combines the convenience families expect with the reporting, reconciliation tools and integrations schools need.

This complementary acquisition strategically expands Finalsite’s K–12 platform. By pairing RevTrak’s trusted payments technology with Finalsite’s school experience solutions, Finalsite offers an integrated, modern solution across the full family journey—enhancing convenience for families and operational efficiencies for schools.

“Families experience their school through every interaction—from their first website visit to enrolling a child, receiving an update or paying for a field trip,” said Jim Calabrese, Finalsite CEO. “Making those moments easier for families must also mean making them easier for school teams to deliver. RevTrak brings proven payments expertise to our broader strategy: a more connected school experience with less administrative complexity behind it.”

Together, Finalsite and RevTrak serve more than 50,000 schools worldwide. Finalsite’s scale and commitment to investment in product innovation, enterprise-grade security, and customer success will accelerate delivery of new payments capabilities to schools while unlocking an easier payment experience for parents.

Finalsite is a portfolio company of Veritas Capital (“Veritas”), a leading investor operating at the intersection of technology and government.

About Finalsite
Finalsite is a K–12 Family Experience Platform serving more than 40,000 schools worldwide, making school easier for families and simpler for school teams to manage.

From the first website visit to enrollment, communications and payments, Finalsite connects the interactions that shape a family’s relationship with their school. By bringing together essential tools, data and workflows, Finalsite helps schools and districts reduce administrative complexity, personalize communications and strengthen enrollment and retention—giving staff more time to serve students and families.

Finalsite is headquartered in Glastonbury, Connecticut with employees across the U.S. and internationally in Canada, Europe and Asia. For more information, please visit www.finalsite.com.

About RevTrak
RevTrak is the complete school payment platform purpose-built for K–12 districts. For more than 30 years, RevTrak has helped district finance teams simplify how schools collect, manage, and track money — across fees, meals, athletics, events, fundraising, registrations and more. Trusted by more than 13,000 schools nationwide, RevTrak integrates with the tools districts already use to give families a modern payment experience and give staff the reporting and reconciliation tools they need.

About Veritas Capital
Veritas is a longstanding technology investor with $54 billion of assets under management and a focus on companies operating at the intersection of technology and government. The Firm invests in companies that provide mission-critical products, services, and software, primarily technology and technology-enabled solutions, to government and commercial customers worldwide. Veritas seeks to create value by strategically transforming the companies in which it invests through organic and inorganic means. Leveraging technology to make a positive impact across vitally important areas, such as healthcare, education, energy, and national security, is core to the Firm. Veritas is a proud steward of national and global assets, focused on improving the quality of healthcare while reducing cost, advancing educational systems, accelerating energy transition, and protecting our nation and allies. For more information, visit www.veritascapital.com.

Finalsite Media Contact
Jon Kannenberg
[email protected] 

Veritas Media Contact
News Media
Prosek Partners
[email protected] 

SOURCE Finalsite

Partnership Will Support New Age Medical’s National Expansion, Entry into New Specialties, and M&A-Driven Growth

STAMFORD, Conn., Sept. 28, 2026 — Avesi Partners (“Avesi”) announced that it has made an investment in New Age Medical (“New Age” or the “Company”), a leading MedTech hub serving the spinal surgery market. Avesi has partnered alongside New Age’s founder and CEO, Kevin Bly, and the Company’s existing management team to support New Age’s mission of enhancing patient care and driving operational efficiency by optimizing and accelerating the flow of medical solutions from manufacturers, through reps, to hospitals, surgeons, and patients.

Headquartered in St. Louis, MO, New Age Medical sits at the intersection of medical device manufacturers, hospitals & ambulatory surgery centers (“ASCs”), surgeons, and medical device sales representatives. New Age works nationwide with 85+ original equipment manufacturers (“OEMs”), 100+ reps, 200+ hospitals/ASCs, and 350+ surgeons, ensuring leading technology is accessible to those who need it. The New Age model reduces supply chain complexity and enables vendor consolidation for hospitals and ASCs, while bringing surgeons and patients the most innovative products OEMs have to offer.

“When we founded New Age Medical in 2012, the goal was simple: make it easier for surgeons to get the right products for their patients, and easier for the manufacturers building those products to reach them,” said Kevin Bly, Founder and Chief Executive Officer of New Age Medical. “Avesi shares our conviction that durable growth is the result of doing right by every stakeholder we serve—surgeons, hospitals, manufacturers, and the reps who bring it all together. The cultural alignment between our two organizations was clear from our very first conversation, as was a shared, growth-oriented mindset. With Avesi’s commitment and resources behind us, we can extend best-in-class product access to more surgeons, more facilities, more reps and ultimately more patients across the country.”

“Avesi has targeted innovative businesses that help hospitals and health systems deliver the highest standards of care while reducing administrative burden,” said Pete Tedesco, Managing Director at Avesi. “New Age delivers this value to its stakeholders and operates in a large, growing market with substantial opportunity to expand. We look forward to pairing our resources and healthcare expertise with the talented team at New Age to continue delivering exceptional service and extend the Company’s impact across new specialties and markets.”

“New Age Medical is one of a kind in its sector given its long-term track record of growth, the strength of its relationships across surgeons, reps, OEMs, and facilities, and the differentiated value it delivers to each,” said Chris Laitala, Managing Partner at Avesi. “Our team at Avesi is excited to work alongside management in the coming years to further expand the Company’s reach and capabilities.”

About New Age Medical

New Age Medical is the MedTech hub that optimizes and accelerates the flow of medical solutions from manufacturers, through reps, to hospitals and surgeons, all with the overarching goal of enhancing patient care and driving operational efficiency. Founded in 2012 and headquartered in St. Louis, MO, New Age works with 85+ OEMs, 100+ reps, 200+ hospitals/ASCs, and 350+ surgeons nationwide, providing top-quality spinal implants, orthobiologics, and related products to ensure exceptional patient care.

For more information, visit https://newagemedical.com/ or https://www.linkedin.com/company/new-age-medical-llc/.

About Avesi Partners

Avesi Partners, with offices in Stamford, CT and Richmond, VA, and over $2.2 billion in assets under management, focuses on partnering with lower-middle market privately held and family-owned businesses in key sectors of the economy, including healthcare services and technology, and business services. Avesi seeks to provide the expertise and resources to empower businesses to attain their full vision in a time and capital efficient manner. Avesi’s goal is to collaborate with families, founders, and executives to accelerate growth and expansion while positioning the businesses to achieve long-term success and enduring value. Target platform companies typically have approximately $5-30 million of EBITDA.

For further information, visit www.avesipartners.com or www.linkedin.com/company/avesi-partners.

New Age Medical Contact
[email protected]

Avesi Contact
[email protected]

SOURCE Avesi Partners

NEW YORK, Sept. 28, 2026 — Infrastructure Capital Advisors, LLC (Infrastructure Capital), a leading provider of investment management solutions designed to meet the needs of income-focused investors, is excited to declare distributions for the Infrastructure Capital Nasdaq Option Income ETF (QVOL), Infrastructure Capital Bond Income ETF (BNDS), Infrastructure Capital Small Cap Income ETF (SCAP), and Infrastructure Capital Equity Income ETF (ICAP). QVOL has declared a distribution increase by $0.05 from $1.04 to $1.09 per share. SCAP has declared a distribution increase by $0.005 from $0.25 to $0.255 per share. ICAP has declared a distribution increase by $0.005 from $0.25 to $0.255 per share. BNDS has declared a distribution increase by $0.0025 from $0.34 to $0.3425 per share.

QVOL intends to target an annualized distribution rate range of between 12% and 15% through option premiums earned from selling call options and dividends received from the Fund’s equity holdings. This target range reflects Infrastructure Capital’s expectations based on the options premiums QVOL seeks to generate and the annualized effect of those premiums. There is no assurance QVOL will achieve its target annualized distribution rate range, and the target annualized distribution rate range does not represent a 12% to 15% yield or a 12% to 15% total return. Actual distributions may be higher or lower depending on market conditions and QVOL’s results. Distributions may include a portion classified as return of capital. Return of capital generally represents a return of a shareholder’s invested capital rather than traditional income such as dividends or interest.

QVOL has declared a monthly distribution of $1.09 per share ($13.08 per share on an annualized basis). 
 

• Ex-Date: Tuesday, September 29, 2026
• Record Date: Tuesday, September 29, 2026
• Payable Date: Wednesday, September 30, 2026

SCAP has declared a monthly distribution of $0.255 per share ($3.06 per share on an annualized basis). 

• Ex-Date: Tuesday, September 29, 2026
• Record Date: Tuesday, September 29, 2026
• Payable Date: Wednesday, September 30, 2026

ICAP has declared a monthly distribution of $0.255 per share ($3.06 per share on an annualized basis). 

• Ex-Date: Tuesday, September 29, 2026
• Record Date: Tuesday, September 29, 2026
• Payable Date: Wednesday, September 30, 2026

BNDS has declared a monthly distribution of $0.3425 per share ($4.11 per share on an annualized basis). 

• Ex-Date: Tuesday, September 29, 2026
• Record Date: Tuesday, September 29, 2026
• Payable Date: Wednesday, September 30, 2026

Infrastructure Capital Advisors expects to declare future distributions on a monthly basis. Distributions are planned, but not guaranteed, for every month. For more information about each Fund’s distribution policy, its 2026 distribution calendar, or tax information, please visit each Fund’s web site for more information.

QVOL is designed to deliver an attractive income stream through a disciplined options-writing strategy, while maintaining the potential for capital appreciation through selective equity positioning. The fund invests at least 80% of its net assets in equity securities and option contracts tied to the Nasdaq, utilizing both quantitative and qualitative analysis to identify relative value opportunities.

“In the current market environment, investors are seeking consistent income without giving up exposure to growth, particularly in the information technology sector,” said Jay Hatfield, CEO and CIO of Infrastructure Capital Advisors. “QVOL is built to monetize the increased volatility we’ve seen across Nasdaq-listed companies through active options strategies while maintaining the careful and pragmatic approach to portfolio and product construction that Infrastructure Capital has become well known for.”

Infrastructure Capital’s suite of dynamic ETFs leverages the firm’s established investment process, including company-level fundamental modeling, valuation-driven price targets, and active volatility management. The firm manages over $4 billion in assets as of 09/28/2026 and delivers income-focused investment solutions to their clients.

QVOL joined the Infrastructure Capital ETF lineup, which includes the Virtus InfraCap U.S. Preferred Stock ETF (NYSE Arca: PFFA), InfraCap REIT Preferred ETF (NYSE Arca: PFFR), InfraCap MLP ETF (NYSE Arca: AMZA), the Infrastructure Capital Equity Income ETF (NYSE Arca: ICAP), Infrastructure Capital Small Cap Income ETF (NYSE Arca: SCAP), Infrastructure Capital Bond Income ETF (NYSE Arca: BNDS) the Infrastructure Capital Preferred Income UCITS ETF (FTSE MIB: PFFI), the Infrastructure Capital S&P 500 Option  Income UCITS ETF (FTSE MIB: SPYC), and  Infrastructure Capital Nuclear Renaissance UCITS ETF (FTSE MIB: NUKZ).

Hatfield is the lead Portfolio Manager for all of the Infrastructure Capital funds and brings more than 30 years of experience to his work on behalf of clients. As of the date of this release, the firm manages more than $4 billion in total assets.

Follow Infrastructure Capital on social media for all of the firm’s need-to-know market commentary and economic outlook at:

Monthly Market and Economic Webinar – Jay Hatfield

Register for our monthly Market & Economic Insights webinar series. Can’t join live each month?  Register anyway and we will email you a playback video link

Income Investing with Infrastructure Capital

Jay D. Hatfield is the Chief Investment Officer for all of the Infrastructure Capital funds and brings more than 30 years of experience to his work on behalf of clients. As of the date of this release, Infrastructure Capital manages over $4B in total assets. 

BNDS ETF strategy is to target high yield investments across fixed-income securities, predominately focusing on corporate bonds. Infrastructure Capital seeks positive security selection versus the benchmark by using a mix of quantitative and qualitative analysis with an emphasis on fixed-income securities that are believed to be undervalued when considering factors such as term premium, credit premium, liquidity premium, industry, sector, and market capitalization.

SCAP ETF seeks total return through a blended approach of capital appreciation and current income. The Fund focuses primarily on the securities of U.S.-listed small cap companies, which is defined as companies with a market capitalization within the range of companies in the Russell 2000 Index. Investments may take the form of common stocks, preferred stocks, convertible securities, debt instruments, equity-linked notes, or other small cap-focused ETFs.

ICAP ETF will primarily invest in equity securities of companies with a strong track record of paying dividends during normal market conditions. The Fund’s portfolio of equities will generally be a diversified selection of securities, including a broad cross-section of sectors and sub-sectors, such as REITs, Utilities, Industrials, pipelines, and financials.

About Infrastructure Capital Advisors
Infrastructure Capital Advisors, LLC (ICA) is an SEC-registered investment advisor that manages exchange traded funds (ETFs) and a series of hedge funds. The firm was formed in 2012 and is based in New York City. ICA seeks total-return opportunities driven by catalysts, largely in key infrastructure sectors. These sectors include energy, real estate, transportation, industrials and utilities. It often identifies opportunities in entities that are not taxed at the entity level, such as master limited partnerships (“MLPs”) and real estate investment trusts (“REITs”). It also looks for opportunities in credit and related securities, such as preferred stocks.

Current income is a primary objective in most, but not all, of ICA’s investing activities.

Consequently, the focus is generally on companies that generate and distribute substantial streams of free cash flow. This approach is based on the belief that tangible assets that produce free cash flow have intrinsic values that are unlikely to deteriorate over time. For more information, please visit infracapfunds.com.

The information contained herein represents our subjective belief and opinions and should not be construed as investment, tax, legal, or financial advice. Investors should consider the investment objectives, risks, charges, and expenses carefully before investing. Please read the prospectus carefully before investing. For more information about Fund strategies or Infrastructure Capital, please reach out to Craig Starr at 212-763-8336 ([email protected]).

The Nasdaq Composite is a stock market index composed of thousands of stocks listed on the Nasdaq Stock Market®, with a particular emphasis on technology-related companies. Established in 1971, it is known for featuring a wide range of companies—from established giants like Apple and Microsoft to smaller, fast-growing firms—reflecting a broad cross-section of the U.S. technology sector. The index is market capitalization-weighted, meaning that larger companies have a greater influence on its overall performance, and it is commonly used as a benchmark to gauge the health and trends of the technology-driven segments of the American economy.

Investors should consider the investment objectives, risks, charges, and expenses carefully before investing. Please read the prospectus carefully before investing. For more information about the Fund, Fund strategies or Infrastructure Capital, please reach out to Craig Starr at 212-763-8336 ([email protected]).

A word about QVOL Risk:  Investing involves risk. Principal loss is possible. The Fund is a recently organized investment company with no operating history prior to the date of this Prospectus. As a result, prospective investors have no track record or history on which to base their investment decision. Derivatives may pose risks in addition to and greater than those associated with investing directly in securities, currencies or other investments, including risks relating to leverage, imperfect correlations with underlying investments or the Fund’s other portfolio holdings, high price volatility, lack of availability, counterparty credit, liquidity, valuation and legal restrictions. Options transactions involve special risks that may make it difficult or impossible to close a position when the Fund desires. The prices of securities the Adviser believes are undervalued may not appreciate as anticipated or may go down, the valuations may never improve or returns on value equity securities may be less than returns on other styles of investing or the overall stock market. Leverage is investment exposure which exceeds the initial amount invested. When the Fund borrows money for investment purposes, or when the Fund engages in certain derivative transactions, such as options, the Fund may become leveraged. A high portfolio turnover rate (portfolio turnover in excess of 100% of the average value of the Fund’s portfolio) has the potential to result in the realization and distribution to shareholders of higher capital gains, which may subject you to a higher tax liability. Please see prospectus for discussion of risks. QVOL fund distributor, Quasar Distributors, LLC.

A word about SCAP risk: Investing involves risk, including possible loss of principal. An investment in the Fund may be subject to risks which include, among others, investing in equities securities, dividend paying securities, utilities, small-, mid- and large-capitalization companies, real estate investment trusts, master limited partnerships, foreign investments and emerging, debt securities, depositary receipts, market events, operational, high portfolio turnover, trading issues, active management, fund shares trading, premium/discount risk and liquidity of fund shares, which may make these investments volatile in price. Foreign investments are subject to risks, which include changes in economic and political conditions, foreign currency fluctuations, changes in foreign regulations, and changes in currency exchange rates which may negatively impact the Fund’s returns. Small and Medium-capitalization companies, foreign investments and high yielding equity and debt securities may be subject to elevated risks. The Fund is a recently organized investment company with no operating history. Please see prospectus for discussion of risks. Diversification cannot assure a profit or protect against loss in a down market. SCAP is distributed by Quasar Distributors, LLC.

A word about ICAP Risk: Investing involves risk, including possible loss of principal. An investment in the Fund may be subject to risks which include, among others, investing in equities securities, dividend paying securities, utilities, preferred stocks, leverage, short sales, small-, mid- and large-capitalization companies, real estate investment trusts, master limited partnerships, foreign investments and emerging, debt securities, depositary receipts, market events, operational, high portfolio turnover, trading issues, options, active management, fund shares trading, premium/discount risk and liquidity of fund shares, which may make these investments volatile in price. Foreign investments are subject to risks, which include changes in economic and political conditions, foreign currency fluctuations, changes in foreign regulations, and changes in currency exchange rates which may negatively impact the Fund’s returns. Small and Medium-capitalization companies, foreign investments, options, leverage, short sales, and high yielding equity and debt securities may be subject to elevated risks. The Fund is a recently organized investment company with no operating history. Please see prospectus for discussion of risks. ICAP fund distributor, Quasar Distributors, LLC.

A word about BNDS risk:  Investing involves risk, including possible loss of principal. An investment in the Fund may be subject to risks which include, among others, investing in fixed income securities, dividend paying securities, utilities, small-, mid- and large-capitalization companies, real estate investment trusts, master limited partnerships, debt securities, market events, operational, high portfolio turnover, trading issues, active management, fund shares trading, premium/discount risk and liquidity of fund shares, which may make these investments volatile in price.  Small and Medium-capitalization companies, and high yielding equity and debt securities may be subject to elevated risks.  New Fund Risk. The Fund is a recently organized investment company with no operating history prior to the date of this Prospectus. As a result, prospective investors have no track record or history on which to base their investment decision. Debt Securities Risk. Increases in interest rates typically lower the value of debt securities held by the Fund. Investments in debt securities include credit risk. Credit Risk. An issuer of debt securities may not make timely payments of principal and interest and may default entirely in its obligations. A decrease in the issuer’s credit rating may lower the value of debt securities. Interest Rate Risk. Securities could lose value because of interest rate changes. For example, bonds tend to decrease in value if interest rates rise. Derivatives Risk. Derivatives may pose risks in addition to and greater than those associated with investing directly in securities, currencies or other investments, including risks relating to leverage, imperfect correlations with underlying investments or the Fund’s other portfolio holdings, high price volatility, lack of availability, counterparty credit, liquidity, valuation and legal restrictions. Options Risk. Options transactions involve special risks that may make it difficult or impossible to close a position when the Fund desires. A fund that purchases options, which are a type of derivative, is subject to the risk that gains, if any, realized on the position, will be less than the amount paid as premiums to the writer of the option. BNDS fund distributor, Quasar Distributors, LLC.

The Funds are distributed either by Quasar Distributors, LLC or by VP Distributors, LLC, an affiliate of Virtus ETF Advisers, LLC. QVOL, ICAP, SCAP, and BNDS ETFs are distributed by Quasar Distributors LLC. PFFA, PFFR, and AMZA ETFs are distributed by VP Distributors, LLC an affiliated of Virtus ETF Advisers, LLC.

Nasdaq® is a registered trademark of Nasdaq, Inc. (which with its affiliates is referred to as the “Corporation”) and is licensed for use by Infrastructure Capital Advisors, LLC. The Product has not been passed on by the Corporations as to its legality or suitability. The Product is not issued, endorsed, sold, or promoted by the Corporations. THE CORPORATIONS MAKE NO WARRANTIES AND BEAR NO LIABILITY WITH RESPECT TO THE PRODUCT.

SOURCE Infrastructure Capital Advisors

SHANGHAI, Sept. 28, 2026 — MOYOM Biotech, a biotechnology company specializing in regenerative aesthetic biomaterials, today announced that it has completed a new financing round from the Cathay Consumer Co-Creation Fund, managed by Cathay Capital. The investment marks an important milestone in the company’s development and will support its next phase of global growth.

The fund was jointly established by Cathay Capital, L’Oréal and the Shanghai Jing’an District Government to foster innovation in beauty, health and skin science. Cathay Capital has built a global investment ecosystem spanning consumer, healthcare and technology, with notable investments including Moonshot AI (Kimi), autonomous driving company Momenta, U.S. fintech company Chime, digital asset platform Ledger, global delivery platform Glovo and AI biotechnology company Owkin.

In addition to identifying emerging brands, investment platforms of this kind can give strategic partners earlier access to emerging technologies, supply-chain capabilities and innovation in adjacent industries. Cathay Capital’s investment in MOYOM reflects growing interest in technologies and biomaterial innovations with the potential to shape the next generation of the beauty and medical aesthetics industry.

Founded in 2018, MOYOM focuses on nanomedical biomaterials and Class III absorbable implantable medical devices, particularly calcium hydroxylapatite (CaHA) regenerative materials. Its flagship brand, Aphranel^®, brings MOYOM’s proprietary biomaterials research to market. Positioned as a new-generation CaHA biostructurer, Aphranel^® is designed to combine immediate structural support, regenerative stimulation and complete biodegradation.

MOYOM’s technology platform is built around two proprietary technologies: ACD-MT^® raspberry-shaped through-hole CaHA microspheres and PCD-ETT^® physically cross-linked CMC gel technology. Together, they are engineered to deliver structural performance, support regenerative interaction and enable controlled biodegradation.

Aphranel^® received Class III medical device registration from China’s National Medical Products Administration (NMPA) in February 2025 and certification under the European Union Medical Device Regulation (EU MDR) in May 2026, establishing a regulatory foundation for international expansion. Since its commercial launch in May 2025, Aphranel^® has been introduced in more than 700 medical aesthetics clinics across China, demonstrating increasing market adoption alongside continued scientific and regulatory progress.

With its proprietary technology platform, key regulatory milestones and growing market presence, MOYOM is entering a new phase of growth. Leveraging Cathay Capital’s global ecosystem, the company plans to accelerate clinical translation, pursue additional regulatory approvals and expand into overseas markets, while continuing to invest in next-generation regenerative biomaterials.

The financing will support MOYOM’s efforts to bring biomaterial innovation originating in China to international markets and establish Aphranel^® as a science-driven regenerative aesthetics brand with global reach.

About MOYOM Biotech

Founded in 2018, MOYOM Biotech develops regenerative aesthetic biomaterials and absorbable implantable medical devices. The company developed Aphranel^®, its flagship CaHA-based regenerative aesthetics brand.

SOURCE MOYOM Biotech

SAN JOSE, Calif., Sept. 25, 2026 — Overlord Labs, Inc., a fabless semiconductor company building battery intelligence infrastructure for compute-intensive, battery-powered devices, today announced the close of its oversubscribed Seed financing, bringing total funding raised to-date to $10 million. The total comprises $7.25 million in Seed financing and the remainder in non-dilutive strategic development funding.

The financing comes as Overlord Labs transitions from tape-out to product validation, following the successful bring-up of its flagship GENESIS™ Battery Intelligence IC, built on the company’s proprietary Silicon × Algorithm Architecture. With silicon operating, the company is advancing validation and preparing to begin customer sampling.

The $4.35 million Seed extension was led by Band of Angels and drew participation from Foothill Ventures, Unlock Pacific Ventures, NuFund Venture Group, Sand Hill Angels and Castle Fund. The round also included returning strategic angel investors, who backed Overlord Labs in its earlier financings and invested additional capital in the extension alongside the new institutional investors.

As compute continues moving to the edge, battery-powered devices are placing unprecedented demands on power efficiency, thermal management, safety and runtime. Traditional fixed-function battery management ICs were not designed for this new generation of intelligent products. Overlord Labs’ Silicon × Algorithm Architecture solves this by building battery intelligence directly into silicon, giving OEMs a more adaptable foundation for these systems.

The first GENESIS™ device targets single-cell systems and is designed to support both established and emerging battery chemistries, including silicon-anode cells. Initial applications include smart glasses, wearables, hearables and other edge AI devices, where rising compute demands must be met within tight battery and form-factor limits.

Overlord Labs will use the capital to complete validation and qualification, support customer sampling and Tier-1 OEM engagements, expand its firmware and battery-algorithm capabilities, and build the production infrastructure needed for commercial scale. The company is targeting volume production in the first half of 2027.

“We started Overlord Labs because battery management architectures were no longer keeping pace with the devices they power,” said Richard Nicholson, Co-Founder and Chief Executive Officer of Overlord Labs. “We now have working silicon, active customer engagement and an investor syndicate, including angels who came back to invest again, that understands the scale of the opportunity. This capital gives us the resources to move GENESIS™ through customer validation and toward production.”

“Hardware OEMs have historically faced a rigid trifecta of trade-offs: performance, form factor, and battery life,” said Carlos Rodriguez, Co-Founder and Chief Operating Officer of Overlord Labs. “We engineered GENESIS™ to break those constraints, giving product teams the software-defined silicon they need to scale all three without compromise. With the Seed financing complete, our focus is getting GENESIS™ into customers’ hands and building the foundation to scale.”

About Overlord Labs
Overlord Labs is a fabless semiconductor company building battery intelligence infrastructure for the next generation of compute-intensive, battery-powered devices. Powered by its proprietary Silicon × Algorithm Architecture, the company’s GENESIS™ Battery Intelligence Platform integrates advanced battery intelligence directly into silicon, enabling OEMs to improve runtime, safety, performance, and design flexibility. Initially focused on wearables, smart glasses, and edge AI devices, the platform is designed to scale across a broad range of battery-powered systems. Headquartered in San Jose, California, Overlord Labs is engineering battery intelligence from the silicon up.

Media Contact
Dianna Rodriguez
Marketing Manager
[email protected]

SOURCE Overlord Labs